Asset

SAB-185

SAB Biotherapeutics Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT04469179phase1unknown2020-08-202021-02-25SAb Biotherapeutics, Inc.Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19
NCT04468958phase1completed2020-07-012020-12-23SAb Biotherapeutics, Inc.Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)